EC Number   |
Application |
Reference |
|---|
   3.4.19.12 | analysis |
the proportion of inclusion-bearing cells showing high levels of ubiquitin C-terminal hydrolase may provide a marker of the activity of a degenerative process |
36450 |
| 3.4.19.12 | analysis |
UCH-L1 is a neuronal marker |
710072 |
| 3.4.19.12 | degradation |
a natural dodecapeptide amide from UCH-L3 with the sequence DPDELRFNAIAL is capable of binding to monoubiquitin and may enable the design of peptides with different affinities towards K48- and K63-linked polyubiquitin |
679222 |
| 3.4.19.12 | degradation |
protein L-isoaspartate O-methyltransferase initiates the repair of isoaspartyl residues in aged or stress-damaged proteins in vivo, e.g. UCHL1 is a substrate for the L-isoaspartate methyltransferase in vivo |
680705 |
| 3.4.19.12 | diagnostics |
ubiquitin C-terminal hydrolase is a biomarker in humans for severe traumatic brain injury |
708233 |
| 3.4.19.12 | diagnostics |
UCH-L1 is a biomarker for ischemic and traumatic brain injury in rats |
708390 |
| 3.4.19.12 | diagnostics |
UCH-L1 is a biomarker for lymph node metastasis in colorectal cancer |
709233 |
| 3.4.19.12 | diagnostics |
UCHL1 is a potential cerebrospinal fluid biomarker of neuronal loss in aneurysmal subarachnoid hemorrhage and presumably other CNS damage and disease states, overview |
709625 |
| 3.4.19.12 | drug development |
the enzyme may contribute to the pathogenesis of idiopathic pulmonary fibrosis and may be a potential therapeutic target |
755443 |
| 3.4.19.12 | drug development |
three-step docking (DOCK, rough GOLD, and fine GOLD) and in vitro enzyme assay methods to identify UCH-L3 inhibitors. UCH-L3 inhibitors may be useful for future apoptosis-inducing anti-cancer drug development |
678612 |
